Journal ArticleDOI
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul Carter,Greg A. Lazar +1 more
Reads0
Chats0
TLDR
This Review focuses on emerging and novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody–drug conjugates, bispecific antibodies and antibody engineering to facilitate more effective delivery.Abstract:
Antibody therapeutics are now established as a major drug class. Here, Carter and Lazar comprehensively discuss current and emerging platforms and technologies for antibody therapeutics, with an emphasis on approaches that could extend their therapeutic applications, including antibody–drug conjugates, bispecific antibodies and antibody engineering to enable more effective delivery.read more
Citations
More filters
Journal ArticleDOI
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen,Philipp Gödel,Marion Subklewe,Hans Joachim Stemmler,Hans A. Schlößer,Max Schlaak,M. Kochanek,B. Böll,Michael von Bergwelt-Baildon +8 more
TL;DR: This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors and gives practical guidance to the management of the cytokine release syndrome.
Journal ArticleDOI
Antibody–drug conjugates for cancer
TL;DR: Recent clinical experience with the approved ADCs and other promising late-stage candidates on the horizon are reviewed, following an overview of the biology and chemistry of ADCs.
Journal ArticleDOI
Unlocking the potential of antibody-drug conjugates for cancer therapy.
TL;DR: In this paper, the authors discuss the current state of knowledge regarding the design, mechanism of action and clinical efficacy of ADCs as well as the apparent limitations of this treatment class, and propose a path forward by highlighting several hypotheses and novel strategies to maximize the potential benefit that ADC can provide to patients with cancer.
Journal ArticleDOI
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.
TL;DR: This work summarizes the recent advances in PPIs modulators, including small molecules, peptides, and antibodies, hoping to provide some guidance to the design of novel drugs targeting PPIs in the future.
Journal ArticleDOI
Laboratory mice born to wild mice have natural microbiota and model human immune responses
Stephan P. Rosshart,Jasmin Herz,Brian G. Vassallo,Ashli Hunter,Morgan Wall,Jonathan H. Badger,John A. McCulloch,Dimitrios G. Anastasakis,Aishe A. Sarshad,Irina Leonardi,Nicholas Collins,Joshua Blatter,Seong-Ji Han,Samira Tamoutounour,Svetlana Potapova,Mark B. St. Claire,Wuxing Yuan,Shurjo K. Sen,Matthew S. Dreier,Benedikt Hild,Markus Hafner,David Wang,Iliyan D. Iliev,Yasmine Belkaid,Giorgio Trinchieri,Barbara Rehermann +25 more
TL;DR: The wildling model fuses lab mouse strains with naturally occurring microorganisms for increased translational research value and closely mirrored the wild mouse immune phenotype in the spleen and blood.
References
More filters
Journal ArticleDOI
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
TL;DR: Experimental and computational approaches to estimate solubility and permeability in discovery and development settings are described in this article, where the rule of 5 is used to predict poor absorption or permeability when there are more than 5 H-bond donors, 10 Hbond acceptors, and the calculated Log P (CLogP) is greater than 5 (or MlogP > 415).
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Related Papers (5)
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more